Study population
Patients participated in one of three multicentre randomised double-blind studies which we have been carrying out (Beasley et al, 1996 (Beasley et al, , 1997 Tollefson et al, 19976) .
Clinical studies
Study 1 (Beasley et al, 1996) compared dose ranges of olanzapine (Sf2.5, 10k2.5, 15f2.5 mg/day) with placebo and with one dose range of haloperidol ( 1 5 f 5 mg/day). All patients met DSM-111-R criteria for schizophrenia (American Psychiatric Association, 1987) . Randomised double-blind acute treatment continued for six weeks. Patients responding to acute treatment continued double-blind treatment for up to 32 months more. Olanzapine patients completing the double-blind extension entered an open-label extension. The Abnormal Involuntary Movement Scale (AIMS; Guy, 1976) was administered halfway through the first week, weekly for six weeks, every two weeks for one year, and every four weeks thereafter.
Study 2 (Beasley et al, 1997) was identical to Study 1 except that a very low-dose of olanzapine (1.0 mg/day) replaced placebo.
Study 3 (Tollefson et al, 19976) compared olanzapine, 5.0 to 20.0 mg/day, with haloperidol, 5.0 to 20.0 mg/day. Patients met DSM-111-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. Randomised, double-blind acute treatment continued for six weeks. Patients responding to acute treatment continued double-blind treatment for up to 19 months more. Patients not responding to double-blind treatment entered the openlabel olanzapine extension at weeks four, five or six. Olanzapine patients completing the double-blind extension entered the open-label extension. The AIMS was administered weekly for six weeks, then every four weeks up to 14 weeks, and every eight weeks thereafter.
The three studies were approved by the ethical review board at each site. Written informed consent was obtained from all patients after procedures and possible adverse events had been explained to them.
In Studies 1 and 2, during the blinded therapy, the investigators adjusted olanzapine and haloperidol within the assigned dose range ( f 2.5 mg or + 5 mg, respectively). In Study 3, each drug could be increased by 5 mg at each visit (up to a maximum of 20 mg/day), or decreased to a minimum of 5 mg/day at any time.
During the open-label extensions, patients could receive 5 to 20 mg/day of olanzapine.
Patient populations
There were 1192 olanzapine patients and 522 haloperidol patients in the analysis of pooled data from the double-blind phases treated for up to 2.6 years. Data for patients in the placebo group of Study 1 have not been included in the comparative analysis of olanzapine and haloperidol, as few patients were followed for more than six weeks, and a placebo group was included in only one of the three pooled studies. The 1.0 mg/day olanzapine treatment group from Study 2 was not pooled with other olanzapine treatment, as it is not a therapeutically effective treatment. The summary incidence of tardive dyskinesia within these groups was calculated. Patients entering the double-blind extensions of Studies 1 and 2 could complete at least one year, and up to 32 months, of doubleblind therapy. Patients still under treatment at the cut-off date for data collection in Study 3 had completed between 22 and 84 weeks of double-blind therapy.
In addition to double-blind data, we analysed both double-blind and open-label data for 1336 olanzapine patients. This includes the 1192 patients treated during double-blind therapy and 144 patients who did not develop tardive dyskinesia, who had crossed over to open-label olanzapine in Study 3. In this analysis, patients were treated for up to 4.9 years.
Assessment criteria
Baseline tardive dyskinesia was assessed by the AIMS and the modified RD-TD criteria of Morgenstern & Glazer (1993) (total AIMS score (sum of the seven anatomical item scores) 2 3 (moderate) and at least one of the seven anatomical item scores 2 2 (mild)). Patients meeting these criteria at either of two baseline AIMS assessments, and patients with a previous diagnosis of tardive dyskinesia, were excluded from the analyses. Patients with fewer than two follow-up AIMS assessments were also excluded from the analyses because they did not have the opportunity to meet criteria for tardive dyskinesia at two consecutive visits.
The criteria for diagnosing tardive dyskinesia during the study were more stringent than the criteria for diagnosing it at baseline. A patient was diagnosed as having tardive dyskinesia if hdshe met the RD-TD criteria of Schooler & Kane (1982) (at least one of the seven anatomical item scores 3 3, or at least two anatomical item scores 2 2 ) at two consecutive AIMS assessments. These consecutive assessments took place from three to seven days apart during the initial six weeks of treatment, and from 14 to 56 days apart during extension treatment. The first visit at which these criteria were met was considered the time of onset. If an assessment was missing, data were not imputed, and the potential observation was not included in the analysis.
Statistical methods
SAS was used for statistical analyses unless otherwise stated. For all analyses, P values were based on two-sided tests.
Kaplan-Meier survival analysis was used to estimate the risk of developing tardive dyskinesia. In computing the survival curves, patients who left the study without meeting criteria for tardive dyskinesia were included in the computation up to the time of discontinuation, and then treated as right-censored observations. Ninety-five per cent confidence intervals for the risk estimates were constructed, using the Kaplan-Meier estimates of risk and Greenwood's variance estimator. The survival curves were compared using StatXact (Cytel Software Corporation, Cambridge, MA) software to derive exact long-rank P values. The relative risk (risk of developing tardive dyskinesia when on haloperidol, compared to olanzapine, at any time point throughout the period of follow-up) and 95% CI were estimated using a Cox proportional hazards model. Appropriate diagnostic plots were examined to check the assumption of proportional hazards.
Relative risk, adjusting for the potential effect of anticholinergic use, was computed using a Cox proportional hazards model. The amount of anticholinergic medication during each interval between visits was incorporated into the model as a timedependent covariate. Analyses were conducted with this covariate as a categorical variable (uselno use) and as a continuous quantitative variable (mean daily benztropine-equivalent dosage). The relative risk, excluding the time-dependent covariate, allowed for assessment of the potential absolute contribution of anticholinergic medication to the observation of tardive dyskinesia.
The incidence rate was estimated as the number of new cases per patient-year at risk. The total number of patient-years of risk was calculated by summing the follow-up time until patients were diagnosed as having tardive dyskinesia, or until discontinuation from observation for patients not diagnosed. Ninety-five per cent CIS were calculated using the bias-corrected and accelerated bootstrap algorithm with 5000 bootstrap resamples for each interval (Efron & Tibshirani, 1993) . The incidence rate ratio was estimated by the ratio of the incidence rates. The confidence intervals, and tests of the hypothesis that the incidence rate ratio was equal to 1, were performed using asymptotic normality of the logarithm of the ratio (Rothrnan, 1986) .
The analysis was stratified into two follow-up time strata because: (a) the studies allowed patients to continue on blinded therapy for more than six weeks only if they were responders; (b) AIMS assessments during the initial six weeks were much more frequent than in other studies of incidence; (c) patients were adapting to marked changes in drug treatment during this period; and (d) there is evidence that the relative risk is not constant over time. In addition to the overall period (baseline up to end of follow-up), these strata were: (a) from baseline up to six weeks (Stratum 1); and (b) longer than six weeks (Stratum 2). Once a patient was diagnosed as having tardive dyskinesia, hdshe could not contribute additional follow-up time. To be included in Stratum 2, the patient must have been free of tardive dyskinesia (using the modified Glazer and Morgenstern criteria) at every assessment during Stratum 1, as well as having had at least two assessments during Stratum 2 (in order to have the opportunity to meet the criteria).
For the overall period and Stratum 2, the risk at one year from the beginning of the stratum was estimated. The risk was not estimated, for Stratum 1, since it lasted only six weeks. The relative risk, incidence rate, and incidence rate ratio were estimated for the overall period, Stratum 1, and Stratum 2.
The analyses of double-blind data were further stratified into two subgroups based on the AIMS: (a) baseline AIMS score=O and (b) baseline AIMS score>O. Analyses of patient and illness characteristics, and baseline severity of illness and EPS, were carried out, to assess potential baseline imbalance. Categorical data were evaluated for treatment differences using the Cochran-Mantel-Haenszel $, which takes into account potential differences across studies. Analysis of variance (ANOVA) was used to evaluate continuous data, including terms for treatment, study, and treatment-by-study interaction.
RESULTS

Patient and illness characteristics
Treatment groups were comparable with respect to gender, race, age, age of onset of psychosis, duration of illness, number of previous episodes and length of current episode. Figure 1 . The number of patients beginning each Sk-month interval at risk is given in the legend. The one-year risk was 2.59% for o h p i n e and 8.02% for baloperidol. The survival curves differed (P<0.001) m favour of olanmpine.
O L A N Z A P I N E A N D T A R D I V E D I S I I W E S I
Diagnostic plots for the propomonal hazards aoalysis for the overall period suggested that the relative risk was not constant over time; therefore, the more reliable relative risk atirmm are from the analyses specific to Stratum 1 and Suamm 2, shown in Table 1 . The majority of casa of fardive dyskinesia were o h e d in Suatum 1; here the difference between the two survival curves was not large (P=0.116).
The one-year risk in Stratum 2 was 0.52% for o h p i n e and 7.45% for halo peridol The survival curves differed (P=0.002) in favour of olanzapine. The relative risk was 11.37, and the ixidewc rau ratio was 11.86. Although the data arc sparse, so that omtidace intervals are wide, the relative risk and kcidratios and confidence intervals are very similar.
The mean (mean of mean daily dose pr patient) doses in Suamm 1 were olampine 1 0 5 mglday, and haloperidol 10.9 mglday. The median obmatiou period until diagnosis or discontinuation in Smtum 1 for olamapine was 42 days (range: 3-64) and for baloperidol 39 days (rangs 457). In Stratum 2, tbe meao doscs were olanzaphe 13.5 mglday, and haloperidol 13.9 mglday. Tbe median observation period for patients in Stratum 2, including the initial observation that they wcre free from tardive dyskinesia in Stratum 1 (42 days), was 260 days for o h p i n e (range: 61-963) and 259 days for baloperidol (range: 70-540).
Rg. I S u n i n l a d~I~d u r b m d y s k h 3 a d a b z a p i m m n s d u d~p t M L d o u b * -
Tdive dyskinesia during double-blind and o p e n -l a b d t h e r a p y There were 1336 patients at the beginning of the follow-up, 448 at the begming of the s a d year, 332 beginning the third year, 108 beginning the fourth year, and five beginning the fifrh year. For the 1336 olaozapine patients with both double-blind and open-label data, the one-year risk for the overall period was 3.08%. The results of the analysis of the overall period and the analym of the two time arata for this population are shown in Table 2 . The one-?ear risk in Stratum 2 was 0.86%. Olz, ohnzapine;TD, urdive dysklnesia. I. The val ues shown repsent the estimated one-par risk (overall period); a d one-year risk fdlowing the initial si x weeks of observation (krrtum 2). mpectivdy.
2.
Value of P from exact log-rank test comparing survival curves.
3. P nlue for ten that Hal-Olz incidence race ratio=l. 
Baseline characteristics and development of tardive dyskinesia
In both the olanzapine and haloperidol groups, the patients who developed tardive dyskinesia did not differ appreciably from those who did not with respect to baseline characteristics (gender, race, age, schizophrenia subtype, course of illness, age at onset, duration of illness, previous number of episodes, length of current episode, BPRS total, positive symptom or negative symptom scores, Simpson-Angus score, Barnes Akathisia Scale score).
DISCUSSION
These studies compared the development of tardive dyskinesia in patients on two different antipsychotics during up to 2.6 years of double-blind treatment. Assessment involved frequent observations (as frequent as every three days), used an objective assessment instrument (AIMS), and used operational diagnostic criteria (RD-TD). In the overall period, the oneyear risk of developing tardive dyskinesia was 2.59% with olanzapine and 8.02% with haloperidol. The survival curves of percentage of patients developing tardive dyskinesia over the course of one year (risk) and the number of cases per patient-year (incidence rate). In these analyses wo cotwtcutive positive waluations were required in order to increau diagnostic validity, while sdll camring cases that might be uansienr. Thev findings, for the overall period, differ from those of most previous studin of the dwelopmmr of tardive dyskinaia over time (Gibson, 1981 ; Kane el ol, 1982 , 1986 Yassa & Nair, 1984; Chouinard 1996) . Firs, the onc-year risk with haloperidol of 8.02% is above the midpoint of the a~u a l incidence range (13-11%) o&ed in previous studies. Second, the majority of cases on borh treatments were diagnosed during Stramm 1: 15/24 on haloperidol and 20124 on olanzapine. The risk with haloperidol was higher than expned, primarily because of the increased number of diagnoses during Stramm 1. This high incidence during Stratum 1 (also observed with olanzapinc) may be, in put, cxplained by the fact that during this suatum, patients in all t h m studies were assessed weekly and assessed twice during the firs week in Studies 1 and 2. Of the 10 other smdies mimed, only five mahated tk prcmce of tardive dyskinesia at several time points, and the frequency of observation ranged from a minimum of two months to a maximum of 12 months. Our frequent diagnostic observations offered more oppormnities to observe elevated AIMS ratings during Stramm 1 than did other studies, and in Stratum 2 within [hex srudies.
There may be other explanations for systematic increases in AlMS scores during Stratum 1. It is thought that a component of the pathophysiology responsible for tardive dyskinesia may involve functional or anatomical upregulation of nigro miaral D2 rcccprm, as a response to chronic exposure to Dz antagonist antipsychotics (Caxy, 1995). Our patients had had a period of 4-11 days free from antipsychotics before k n n i n g the observation period, and the D, antagonist activities of the olanzapine and haloperidol doses were relatively modest. Therefore, the patients were prone to develop withdrawal dyskinesia symptoms during Stratum 1. Although they were continuing to receive a Dz anragoniq the effective dose of D, anragonism had been reduced relative to the prelrudy d m . T h m parients who rner RD-TD criteria were counted as caw. This hypothesis of withdrawal dyskincria occurring during Stratum 1 is supported by the observation that 2.1% of patients free of tardive dyr kinesia at baseline who were treated with placebo or olaruapinc 1 mglday met the criteria for dyskinesia during S t r a w 1. and this is comparable to the incidence for olanzapine 11.7%) and haloperidol (2.9%).
Given the difference between results and methods in Stratum 1 and t h m of p m vious studies, it may be more appropriate to fonu on Stratum 2 to estimate both absolute risk with olanzapine and relative risk compared with haloperidol. The one-year risk in this nratum was 0.52% for olanzapine and 7.45% for haloperidol. The survival curves diffcred in favour of olanzapine (P=0.002). The relative risk was 11.37, and the incidence rate ratio was 11.86. The greater relative difference (more than tenfold) in rate of development of dyskinesia during Stratum 2, compared to the relative difference in incidence (two to four times) which we have previously reported (l'ollefion ef a/, 1997a). underscores the imporram of considering the time to development The important cliical and public health quadon is the risk of development of an adverse event during a specific length of time of treatment.
It may be that some cases of tardive dyskinaia in Stratum 2 are cases of withdrawal dyskinesia. If patients become c w d y noncompliant during long-term treatment, they may suffer from withdrawal dyskinesia. In general, olanzapine is bener tolerated than haloperidol, at least during acute treatment (Beasley et a/. 1996, 1997; Tollefson n a/, 19976). Therefore, non-compliance could have brm greater during long-term therapy among the haloperidol-treated patients, and this in turn could have contributed to the difference in observed rams of dyskinesia development. Stratification of the analysis ar six weeks was based on the potential for withdrawal dyskinesia, but also the shih to less frequent AlMS assessment and the forced discontinuation of non-responding patients at that time.
Anodur diinction between the prcxnt analyses and previous studies is that vveral of the studies included larger numbers of patients followed for longer periods of time. The Yale group followed an initial cohort of over 300 patients for five years, and approximately 186 at-risk parients entered the fihh year. In our doublc-blind studies, 129 olanzapine patients entered the xcond year of obvrvarion but only three entered the third year. Although it may be possible to gcncralise these olanzapine results over at least one year of ueatment, the small number of patients observed for longer than 18 monrhs (n=l8) may raise questions about whether results can be generalixd over periods greater than 12-18 months. To look into this, we also a n a l y d all olanzapine data, not just doubleblind data. This is consistent with previous d i e s of incidence, as none were randomiscd, and all involved open-label treatment. With the entirety of olanzapim data, 108 patients entered the fourth and five entered the fihh year of observation. This should afford reasonable confidence in the generalisation of risk estimation into the fourth year. The studies of Yassa & Nair (1984) .
Chouinard et a1 (1986) and Chakos d a1 (1996) included between 108 and 131 patients, and the studies of Waddington et a1 (1990) and Gardm et a1 (1988) involved fewer than 100 patients each. In the original study by Kane n a1 (1982) . only 139 patients entered the third year. Following the initial six weeks of treatment, the risk of tardive dyskinesia was 0.86% at one year (total of one year and six weeks treatment) for the entirery of the olanzapine data. The oneyear risk was somewhat higher than that for the dwble-blind data (0.52%). but still substantially less than the admates for conventional antipsychotics bawd on past studies and the doubleblind haloperidol results prerented here. All the olanzapinc data confirm that the doublc-blind findings could be generalixd to cover a longer-tcm, and indicate that the risk of dyskinesia remained relatively low for at least three years of olanzapine treatment.
Since patients who did not respond to double-blind treatment I& the study aher six weeks, these double-blind resulu cannot be gcncralised to long-term treatment in non-responding patients. However, the divontinuation of non-responding patients is consistent with clinical practice, where alternative therapies would be tied. Furthermore, patients not responding m douhle-blind haloperidol or olaruapim conmbuted to the open-label olanzapine findings.
The d m ranges of olanzapine and haloperidol differed between smdia and (although considered therapeutic) may nor reprsmt the ranges u d in clinical practice. Dcquivalmcg, with mpm to efficacy, is important in considering differenccn in outcome regardii development of dyskimsia. In Study 1, olanzapine 15k2.5 mglday ourperformed haloperidol 15+S mglday, olanzapine 10k2.5 mgl day war equivalent, and olanzapine 5j12.S mglday was associated with slightly more &an half the decrement in BPRS total score compared to haloperidol (Beasley et al, 1996) . In Study 2, all three dose arms of olanzapine, including the 5 f2.S mg/ day arm, were numerically more efficacious than the haloperidol arm (Beasley et al, 1997) . In Study 3, where patients were titrated m an optimal blinded dose between 5 and 20 mg/day for both drugs, olanzapine showed greater efficacy (Tollefson et al, 19976) . From these results, it would not appear that use of doses of olanzapine with lesser efficacy than the doses of haloperidol influenced these findings, especially since the olanzapine 5f2.5 mglday arm conmbuted only a small minority of patients to the olanzapine pool.
Anticholinergic administration has been linked to dyskinesias (Cardos & Cole, 1983) . It would be expected that, given the reduced acute EPS with olanzapine, there would be more anticholinergic use with haloperidol. This could conmbute to the differences in the incidence of dyskinesias between the two treatments. However, when anticholinergic use was modelled as a timedependent covariate in the proportional hazards model, the relative risk for haloperidol remained elevated. This indicates that, although haloperidol patients received more anticholinergic than 'lampine 01, 1986; Kane et al, 1986) emerged (Table 3) : (a) with both treattreatment. The mean duration of psychotic suggest that baseline Parkinsonism is a risk ments, the rate of tardive dyskinesia when illness was 12.7 years for the olanzapine factor for tardive dyskinesia. There was, the baseline AIMS score was >O was group and 13.5 years for the haloperidol however, no difference between the olanzahigher than when the score was 0 (as exgroup. Virtually every patient entered into pine group and the haloperidol group with pected); and (b) when considering the such studies has received antipsychotic regard to baseline severity of Parkinsonian overall period, the relative risk for olanzamedication. In Study 3, the largest contrisymptoms.
pine v. haloperidol was even greater for butor to these data, less that 5% of 1996 The presence of baseline dyskinesias patients with no dyskinesias at baseline patients had not previously received a D, below the threshold of severity for a diagthan for those patients with symptoms at antagonist. The Yale group (Morgenstern nosis was assessed as a potential confound baseline (4.09 v. 1.81). Thus, the higher & Glazer, 1993) have found past of these findings. It was hypothesised that risk of developing tardive dyskinesia with antipsychotic exposure to have a strong the presence of such symptoms at baseline haloperidol does not appear to result from influence on the incidence of dyskinesia would be associated with a higher incia higher frequency of dyskinesias at baseand, as discussed above, it is clear that in dence of dyskinesias meeting RD-TD criline in this group. patients free of dyskinesias at baseline, teria. In order to evaluate the influence These data do not allow an estimate of there is a reduced incidence, relative to paof baseline dyskinesias, the double-blind the risk of tardive dyskinesia in patients tients with some symptoms at baseline.
In spite of the inability to precisely quantify the risk to new patients, naive to antipsychotics, treated with olanzapine, these results allow quantification of risk in a clinically relevant population of patients in their mid-thirties with chronic symptomatology and histories of treatment for more than ten years. When early onset cases (observed during the first six weeks) were excluded, the risk of tardive dyskinesia at one year was 0.5% considering double-blind data and 0.9% considering all data. Furthermore, the relative risk was 11.4 ames greater with haloperidol than with olanzapine over at leas one year of therapy following the initial six weeks of stabilisation.
